<DOC>
	<DOCNO>NCT00003313</DOCNO>
	<brief_summary>RATIONALE : Amifostine may effective treatment toxic side effect cause radiation therapy chemotherapy . It yet know whether chemotherapy radiation therapy effective without amifostine non-small cell lung cancer . PURPOSE : Randomized phase III trial determine effectiveness amifostine treat patient stage II stage III non-small cell lung cancer surgically remove undergoing chemotherapy radiation therapy .</brief_summary>
	<brief_title>Amifostine Treating Patients With Stage II Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate whether addition radioprotector amifostine reduce incidence severity non-hematologic toxicity , specifically esophagitis pneumonitis , concurrent hyperfractionated radiotherapy chemotherapy ( paclitaxel carboplatin ) patient stage II , IIIA , IIIB non-small cell lung cancer . II . Evaluate difference quality life symptom distress , specifically dysphagia , patient receive amifostine receive amifostine . III . Evaluate relationship tobacco use alcohol use treatment appraisal quality life symptom distress , specifically esophagitis , two group . IV . Evaluate efficacy induction therapy paclitaxel carboplatin follow concurrent chemotherapy hyperfractionated radiotherapy patient . OUTLINE : This open-label treatment randomize supportive care study . Patients stratify accord disease stage ( II v IIIA v IIIB ) , Karnofsky performance status ( 90-100 % vs 70-80 % ) , age ( 70 vs 70 ) . Patients randomize one two treatment arm . Arm I : Patients receive paclitaxel IV 3 hour day 1 22 1 hour weekly 6 week begin day 43 . Patients receive carboplatin IV 30 minute immediately paclitaxel dose . Patients receive filgrastim ( G-CSF ) subcutaneously 10-14 day first two paclitaxel carboplatin dos . Radiotherapy begin day 43 administer twice daily 5 day per week 6 week . Beginning day 43 , patient receive amifostine IV 5-7 minute 4 day week 6 week . Arm II : Patients receive treatment arm I without amifostine . Quality life assess baseline , chemoradiation ( 2 course induction chemotherapy ) , last week chemoradiation ( week 6 ) , 6-week follow-up visit . Patients follow 1 month , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 244 patient ( 122 per treatment arm ) accrue study within 38 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable stage II , IIIA , IIIB nonsmall cell lung cancer No distant metastases No prior complete ( gross subtotal ) tumor resection No postresection intrathoracic tumor recurrence Pleural effusion see chest xray allow appear thoracotomy invasive thoracic procedure ( pleural effusion acceptable see CT scan , chest xray ) Must ineligible refuse participation protocol RTOG9309 PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 2,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL* SGOT great 1.5 time upper limit normal* * Unless due document benign disease Renal : Creatinine great 1.5 mg/dL Cardiovascular : No myocardial infarction within past 6 month No symptomatic heart disease , include angina , congestive heart failure , uncontrolled arrhythmia Other : No weight loss great 5 % 3 month prior diagnosis No prior concurrent invasive malignancy within past 3 year except nonmelanomatous skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior thoracic neck radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>oral complication</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>radiation toxicity</keyword>
</DOC>